BioInnovation Institute backs 17 early-stage startups with €9.5M

BioInnovation Institute is putting €9.52 million into 17 research-based startups through its Venture Programme, giving each company a €560,000 convertible loan plus access to its network, labs and business support in Copenhagen.

The money arrives just after the Novo Nordisk Foundation said it would add €736 million more to BII. That backing gives the Danish institute room to grow fast: it wants to lift the number of startups it supports each year from around 20 to 30, and to push further across Europe, not just at home.

The pitch is straightforward, and pretty ambitious. BII wants to take research from universities and hospitals and help it become something that can actually be sold, funded and scaled. That means more than cash. The selected companies will get help with science, team-building, fundraising and the sort of practical stuff that usually decides whether a promising project becomes a business or just another slide deck.

The 17 startups cover a lot of ground: green hydrogen, women’s health, methane measurement, eye therapies, bioplastics, kidney disease, surgical smoke analysis, medical imaging, protein design, food proteins, educational AI, chemical alternatives, methane-to-syngas conversion, metabolic treatments, photonic hardware, microfabrication and chip-scale light control. It’s a neat snapshot of where research money is heading right now: climate, biotech and AI, with a lot of engineering in the middle.

BII says it has already backed more than 140 companies since it was set up. With this new funding, it clearly wants to be more than a local incubator with a nice lab in Copenhagen. It wants to be a European pipeline for turning good science into businesses that can leave the building.